This chapter focuses on imaging methods, including computed tomography, positron emission tomography and magnetic resonance in the diagnosis and staging of gastrointestinal stromal tumors. Shin S, Choi H. In: Gastrointestinal Stromal Tumors . Edited by Scoggins CR et al. Springer International Publishing Switzerland, 2017. doi:10.1007/978-3-319-42632-7_6

Endoscopic removal of gastrointestinal stromal tumors originating from the muscularis propria layer by a trained endoscopist appears to be safe and feasible, based on this retrospective review of North American patients. Andalib I et al. Surg Endosc 2017. doi:10.1007/s00464-017-5862-9

Scola et al. present a series of computed tomography scans that highlight the wide array of clinical presentations and imaging characteristics associated with a gastrointestinal stromal tumor diagnosis. Scola D et al. Abdom Radiol 2017; 42: 1350–1364. doi:10.1007/s00261-016-1025-z

Ang and Maki provide an overview of the contemporary therapeutic landscape of metastatic gastrointestinal stromal tumors in light of the introduction of kinase inhibitors such as imatinib. Ang C, Maki RG. Oncol Ther 2016; 4: 1–16. doi:10.1007/s40487-015-0014-7

Sato et al. investigate whether surgical interventions and/or tyrosine kinase inhibitor therapy confer a greater survival benefit in gastrointestinal stromal tumor patients. Sato S et al. Surg Today 2017; 47: 58–64. doi:10.1007/s00595-016-1351-3

In this retrospective analysis, Kramer et al. evaluate the clinicopathological features of gastrointestinal stromal tumors in patients younger than 50 years to identify potential age and gender-related effects on patient outcome. Kramer K et al. BMC Cancer 2015; 15: 57. doi:10.1186/s12885-015-1054-y

Maurel et al. question the viability of phosphorylated-insulin growth factor I receptor and metalloproteinase-3 expression as biomarkers for gastrointestinal stromal tumor prognosis in this retrospective study. Maurel J et al. Clin Sarcoma Res 2016; 6: 10. doi:10.1186/s13569-016-0050-6

Watson et al. discuss the clinical evolution of gastrointestinal stromal tumor detection and management, specifically considering advancements in diagnosis and management over the last three decades. Watson GA et al. Ir J Med Sci 2016; 185: 319–326. doi:10.1007/s11845-016-1410-1

This chapter on gastrointestinal stromal tumors contextualizes current diagnostic, staging and treatment strategies employed clinically by highlighting key aspects of the disease’s cellular and molecular pathology. Kollàr A. In: International Manual of Oncology Practice . Edited by de Mello RA et al. Springer International Publishing Switzerland, 2015. doi:10.1007/978-3-319-21683-6_31

Coe and Sicklick highlight the known epidemiological factors associated with gastrointestinal stromal tumors (GISTs) and discuss how the understanding of the patient- and disease-related characteristics of GIST has evolved over the last two decades. Coe TM, Sicklick JK. In: Gastrointestinal Stromal Tumor . Edited by Scoggins CR et al. Springer International Publishing Switzerland, 2016 doi:10.1007/978-3-319-42632-7_2

Guller et al. present findings challenging the view that small bowel gastrointestinal stromal tumor is associated with poorer cancer-specific survival and overall survival in this large population-based study. Guller U et al. Gastric Cancer 2017; 20: 49–60. doi:10.1007/s10120-015-0571-3

This multicentre phase II trial (DOVIGIST) shows the promise of dovitinib as an active treatment for gastrointestinal stromal tumour patients who are refractory or intolerant to imatinib. Br J Cancer 2017. doi: 10.1038/bjc.2017.290

In this chapter, Racz et al. succinctly outline surgical work-up, management and follow-up guidelines for gastrointestinal stromal tumor resection. Racz J et al. In: Gastrointestinal Stromal Tumours . Edited by Wright F et al. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-26276-5_11

Zitvogel et al. evaluate growing evidence implicating the immune system in patient responses to imatinib mesylate for treatment of gastrointestinal stromal tumor. Nat Rev Clin Oncol 2016; 13: 431–446. doi:10.1038/nrclinonc.2016.41